SILO PHARMA, INC. Sale of Stock, Consideration Received Per Transaction
SILO PHARMA, INC. (SILO) had Sale of Stock, Consideration Received Per Transaction of $518.23 thousand as of 2025-07-29, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedPerTransaction · last filed 2026-08-13
- 2025-07-29: Sale of Stock, Consideration Received Per Transaction $518.23K.
| Period end | Sale of Stock, Consideration Received Per Transaction |
|---|---|
| 2025-07-29 | $518.23K 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |